Skip to Content

Interferon alfacon-1 Disease Interactions

There are 10 disease interactions with interferon alfacon-1:

Major

Interferon Alfa (Includes Interferon alfacon-1) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also be reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Major

Interferon- Alfa (Includes Interferon alfacon-1) ↔ Autoimmune Diseases

Severe Potential Hazard, Moderate plausibility

Applies to: Autoimmune Disorder

Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis. Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Major

Interferon-Alfa (Includes Interferon alfacon-1) ↔ Hepatic Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy. Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment. Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease. Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Major

Interferons (Includes Interferon alfacon-1) ↔ Cardiac Disease

Severe Potential Hazard, High plausibility

Applies to: Ischemic Heart Disease, Arrhythmias, Congestive Heart Failure

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
  3. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
View all 4 references
Major

Interferons (Includes Interferon alfacon-1) ↔ Cns Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Psychosis, Parkinsonism, Seizures

Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  3. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
View all 4 references
Major

Interferons (Includes Interferon alfacon-1) ↔ Depression

Severe Potential Hazard, Moderate plausibility

Applies to: Depression

Interferons (alfa or beta) can induce depression and suicidal behavior. Suicidal attempts and suicides have been reported. Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression. Clinical monitoring of psychological status is recommended.

References

  1. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
  2. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
  3. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
View all 4 references
Major

Interferons (Includes Interferon alfacon-1) ↔ Thyroid Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Hypothyroidism, Hyperthyroidism

Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons. Therapy with interferons should be administered cautiously to patients with thyroid dysfunction. If thyroid control can not be maintained within normal limits with medication, interferon-alfa should be discontinued. Clinical monitoring of thyroid function is recommended.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Moderate

Interferon Alfa (Includes Interferon alfacon-1) ↔ Diabetes Mellitus

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients. Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus. Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Moderate

Interferons (Includes Interferon alfacon-1) ↔ Myelosuppression

Moderate Potential Hazard, High plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression. Leukopenia is the primary manifestation. Thrombocytopenia and anemia occur less frequently. Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression. Clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Moderate

Interferons (Includes Interferon alfacon-1) ↔ Peripheral Neuropathy

Moderate Potential Hazard, Moderate plausibility

Applies to: Peripheral Neuropathy

Paresthesia and numbness have been reported during interferon therapy. Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.

interferon alfacon-1 drug Interactions

There are 186 drug interactions with interferon alfacon-1

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide